Clinical significance of serum diamine oxidase activity in inflammatory bowel disease: Importance of evaluation of small intestinal permeability

Inflammatory Bowel Diseases

Volumn 17, Issue 2, 2011, Pages

  Honzawa, Yusuke ^a   Nakase, Hiroshi ^a   Matsuura, Minoru ^a   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (COPPER CONTAINING);

ADULT; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; ENZYME ACTIVITY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADULT; AMINE OXIDASE (COPPER-CONTAINING); CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INTESTINE, SMALL; MALE; MIDDLE AGED; PERMEABILITY;

EID: 78651321736     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21588     Document Type: Letter

References (11)

1. Zeissig S, Bürgel N, Günzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007; 56: 61-72.
2. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005; 129: 550-564.
3. Wyatt J, Vogelsang H, Lochs H, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet. 1993; 341: 1437-1439.
4. Salim SY, Söderholm JD,. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2010 [Epub ahead of print].
5. Shakir KM, Margolis S, Baylin SB,. Localization of histaminase (diamine oxidase) in rat small intestinal mucosa: site of release by heparin. Biochem Pharmacol. 1977; 26: 2343-2347.
6. Ayuso P, Garcia-Martin E, Martinez C, et al. Genetic variability of human diamine oxidase: occurrence of three nonsynonymous polymorphisms and study of their effect on serum enzyme activity. Pharmacogenet Genomics. 2007; 17: 687-693.
7. Palacios NL, Agundez JA, Diaz-Rubio M, et al. Analysis of a non-synonymous single nucleotide polymorphism of the human diamine oxidase gene (ref. SNP ID: rs1049793) in patients with Crohn's disease. Scand J Gastroenterol. 2009; 9: 1-6.
8. Takagi K, Nakao M, Ogura Y, et al. Sensitive colormetric assay of serum diamine oxidase. Clin Chim Acta. 1994; 226: 67-75.
9. Arrieta MC, Madsen K, Doyle J, et al. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut. 2009; 58: 41-48.
10. Olson TS, Reuter BK, Ley K, et al. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med. 2006; 203: 541-552.
11. Schreiber S, Reinisch W, Vanasek T, et al. Traficet-en, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of protect-1 in Crohn's disease. Gut. 2008; 57 (suppl II) A1.